DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Luca Issi - 1 Issi - 1 Issi's - 1 Issa - 1 GSD1a - 1
Top related locs:
Top related orgs:
Ultragenyx Pharmaceutical - 1 RBC Capital Markets - 1 U.S . Food - 1 Drug Administration - 1

Search resuls for: "Ultragenyx Pharmaceutical"


3 mentions found


☆ Buy this little-known pharma stock with more than 80% upside ahead, RBC says
  + stars: | 2024-04-22 | by ( Pia Singh | ) www.cnbc.com   time to read: +3 min
Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.
Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration
☆ TipRanks reveals the top 10 health care sector analysts of the past decade
  + stars: | 2023-05-21 | by ( Tipranks.Com Staff | ) www.cnbc.com   time to read: +5 min
TipRanks leveraged its Experts Center tool to recognize the ones with a high success rate. We also analyzed each stock recommendation made by health care sector analysts in the past decade. TipRanks' algorithms calculated the statistical significance of each rating, average return and the analysts' overall success rate. The buy recommendation generated a return of 397.9% from May 12, 2020 to May 12, 2021. Boris Peaker - TD CowenBoris Peaker has the 10th spot on the list, with a success rate of 47%.
☆ Analysts' favorite growth stocks for 2023 include two electric vehicle charging companies expected to double
  + stars: | 2022-12-25 | by ( Fred Imbert | ) www.cnbc.com   time to read: +3 min
It has been a year to forget for growth stocks. This also marks the first time since 2016 that growth has lagged value, comparing the growth ETF to the iShares Russell 1000 Value ETF (IWD) . Growth stocks are characterized by those that tend to trade on the expectation of strong earnings expansion over several years in the future, rather than here and now. Despite this tough year, analysts expect big gains from some growth companies in 2023. More than three-quarters of analysts covering ChargePoint rate it a buy, while Plug Power has buy ratings from nearly two-thirds of analysts covering it.
0 next >>
Total: 3